BAX
Price
$30.97
Change
+$0.02 (+0.06%)
Updated
Jan 17, 04:59 PM (EDT)
Capitalization
21.77B
12 days until earnings call
ICAD
Price
$1.97
Change
+$0.07 (+3.68%)
Updated
Jan 17 closing price
Capitalization
42.43M
39 days until earnings call
Ad is loading...

BAX vs ICAD

Header iconBAX vs ICAD Comparison
Open Charts BAX vs ICADBanner chart's image
Baxter International
Price$30.97
Change+$0.02 (+0.06%)
Volume$25.61K
Capitalization21.77B
iCAD
Price$1.97
Change+$0.07 (+3.68%)
Volume$699.39K
Capitalization42.43M
BAX vs ICAD Comparison Chart
Loading...
BAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BAX vs. ICAD commentary
Jan 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a Hold and ICAD is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 18, 2025
Stock price -- (BAX: $30.95 vs. ICAD: $1.90)
Brand notoriety: BAX and ICAD are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BAX: 142% vs. ICAD: 27%
Market capitalization -- BAX: $21.77B vs. ICAD: $42.43M
BAX [@Medical Specialties] is valued at $21.77B. ICAD’s [@Medical Specialties] market capitalization is $42.43M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BAX’s FA Score shows that 2 FA rating(s) are green whileICAD’s FA Score has 0 green FA rating(s).

  • BAX’s FA Score: 2 green, 3 red.
  • ICAD’s FA Score: 0 green, 5 red.
According to our system of comparison, BAX is a better buy in the long-term than ICAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BAX’s TA Score shows that 4 TA indicator(s) are bullish while ICAD’s TA Score has 6 bullish TA indicator(s).

  • BAX’s TA Score: 4 bullish, 4 bearish.
  • ICAD’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, ICAD is a better buy in the short-term than BAX.

Price Growth

BAX (@Medical Specialties) experienced а +4.60% price change this week, while ICAD (@Medical Specialties) price change was -3.06% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.88%. For the same industry, the average monthly price growth was +5.52%, and the average quarterly price growth was +1.41%.

Reported Earning Dates

BAX is expected to report earnings on Apr 24, 2025.

ICAD is expected to report earnings on May 19, 2025.

Industries' Descriptions

@Medical Specialties (+0.88% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BAX($21.8B) has a higher market cap than ICAD($42.4M). BAX YTD gains are higher at: 6.139 vs. ICAD (3.825). BAX has higher annual earnings (EBITDA): 1.67B vs. ICAD (-12.18M). BAX has more cash in the bank: 3.19B vs. ICAD (19M). ICAD has less debt than BAX: ICAD (514K) vs BAX (14.4B). BAX has higher revenues than ICAD: BAX (14.8B) vs ICAD (25.4M).
BAXICADBAX / ICAD
Capitalization21.8B42.4M51,415%
EBITDA1.67B-12.18M-13,732%
Gain YTD6.1393.825160%
P/E Ratio85.61N/A-
Revenue14.8B25.4M58,268%
Total Cash3.19B19M16,811%
Total Debt14.4B514K2,801,556%
FUNDAMENTALS RATINGS
BAX vs ICAD: Fundamental Ratings
BAX
ICAD
OUTLOOK RATING
1..100
1313
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
36
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8992
PRICE GROWTH RATING
1..100
6142
P/E GROWTH RATING
1..100
19100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BAX's Valuation (6) in the Medical Specialties industry is in the same range as ICAD (36) in the Computer Peripherals industry. This means that BAX’s stock grew similarly to ICAD’s over the last 12 months.

BAX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ICAD (100) in the Computer Peripherals industry. This means that BAX’s stock grew similarly to ICAD’s over the last 12 months.

BAX's SMR Rating (89) in the Medical Specialties industry is in the same range as ICAD (92) in the Computer Peripherals industry. This means that BAX’s stock grew similarly to ICAD’s over the last 12 months.

ICAD's Price Growth Rating (42) in the Computer Peripherals industry is in the same range as BAX (61) in the Medical Specialties industry. This means that ICAD’s stock grew similarly to BAX’s over the last 12 months.

BAX's P/E Growth Rating (19) in the Medical Specialties industry is significantly better than the same rating for ICAD (100) in the Computer Peripherals industry. This means that BAX’s stock grew significantly faster than ICAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BAXICAD
RSI
ODDS (%)
Bullish Trend 4 days ago
56%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 4 days ago
88%
Momentum
ODDS (%)
Bullish Trend 4 days ago
53%
Bullish Trend 4 days ago
85%
MACD
ODDS (%)
Bullish Trend 4 days ago
44%
Bullish Trend 4 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
52%
Bearish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
64%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
48%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 19 days ago
58%
Bearish Trend 8 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
63%
N/A
Aroon
ODDS (%)
Bearish Trend 4 days ago
61%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Ad is loading...
BAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY591.64-1.14
-0.19%
SPDR® S&P 500® ETF Trust
BTC.X99756.910000-747.585940
-0.74%
Bitcoin cryptocurrency
GME27.72-0.24
-0.86%
GameStop Corp
TSLA413.82-14.40
-3.36%
Tesla
AAPL228.26-9.61
-4.04%
Apple

BAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BAX has been loosely correlated with ICUI. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then ICUI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BAX
1D Price
Change %
BAX100%
+2.45%
ICUI - BAX
39%
Loosely correlated
-0.33%
TFX - BAX
38%
Loosely correlated
+2.78%
MDT - BAX
37%
Loosely correlated
+2.06%
BRKR - BAX
35%
Loosely correlated
+2.57%
BSX - BAX
35%
Loosely correlated
+1.32%
More

ICAD and

Correlation & Price change

A.I.dvisor tells us that ICAD and VMD have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ICAD and VMD's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICAD
1D Price
Change %
ICAD100%
+1.06%
VMD - ICAD
29%
Poorly correlated
-1.21%
HYPR - ICAD
29%
Poorly correlated
+0.95%
BAX - ICAD
27%
Poorly correlated
+2.45%
EW - ICAD
26%
Poorly correlated
-0.60%
VCYT - ICAD
25%
Poorly correlated
-1.49%
More